PMCB — Stock Film
STOCK FILMSCENE 1/11PMCB · $0.61
Stock Expert AI presents
PMCB
PharmaCyte Biotech, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
PharmaCyte Biotech, Inc. A quick introduction.

On the stock market since 2013, it operates in the world of health and science. It has 2 employees. Now — the numbers.

on the stock market since 2013
2 employees
$4.1M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, less than $1 stays as net profit.

This is an established company with proven profits.

Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $15.5M would still be left in the vault — a solid cushion for hard times.

What executives did with their own stock over the last 12 months:
23 buy5 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
40
weak

Clearly below the class average.

FINANCIAL STRENGTH
59
average

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
69
strong

Clearly above the class average — a step short of the very top.

GROWTH
87
very strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
26
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Thin profit on each sale3/10
The stock has lost its spark3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $15.5M in the vault; even if every debt were paid off, $15.5M would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 23 buys and 5 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Trading under $1

The stock sits at $0.61. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 26/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
The business trails its class

Measured against its sector, the quality of the business sits below the class average. Report-card grade: 40/100.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, PMCB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: PMCB is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film